Your browser doesn't support javascript.
loading
Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma.
Weber, Jeffrey S; Levinson, Benjamin A; Laino, Andressa S; Pavlick, Anna C; Woods, David M.
Affiliation
  • Weber JS; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health.
  • Levinson BA; Division of Biostatistics, Department of Population Health, NYU Grossman School of Medicine, New York, New York.
  • Laino AS; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health.
  • Pavlick AC; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health.
  • Woods DM; Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Melanoma Res ; 32(5): 324-333, 2022 10 01.
Article in En | MEDLINE | ID: mdl-35678233
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Melanoma Limits: Humans Language: En Journal: Melanoma Res Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Melanoma Limits: Humans Language: En Journal: Melanoma Res Journal subject: NEOPLASIAS Year: 2022 Document type: Article Country of publication: